May 2026
1. TELLES R, Thaker PH, Goodheart MJ, Penedo FJ, et al
   Rethinking depression diagnosis in ovarian cancer: The role of somatic symptoms.
   Cancer. 2026;132:e70344.
   

   >> Share

   
   
2. LI L, Song N, Zhang D, Li Y, et al
   Multigene germline testing for epithelial ovarian cancer in China.
   Cancer. 2026;132:e70395.
   

   >> Share

   
   February 2026
3. LAWRENCE L
   Immunochemotherapy regimen demonstrates survival benefits for patients with platinum-resistant ovarian cancer.
   Cancer. 2026;132:e70251.
   

   >> Share

   
   
4. 
   Correction to "Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial".
   Cancer. 2026;132:e70324.
   

   >> Share

   
   
5. SHAN Y, Ding B, Ji F, Lin H, et al
   T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cancer.
   Cancer. 2026;132:e70279.
   

   >> Share

   
   
6. O'CONNELL CP, Berndt SI, Chudy-Onwugaje K, Kunzmann A, et al
   Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
   Cancer. 2026;132:e70201.
   

   >> Share

   
   November 2025
7. FITCH KC, Yang JC, Ryan ES, Monuszko KA, et al
   Preferences of BRCA mutation carriers for attributes of risk-reducing surgical options for breast and ovarian cancer.
   Cancer. 2025;131:e70148.
   

   >> Share

   
   September 2025
8. YOSHINO Y, Furusawa A, Nara K, Taguchi A, et al
   Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab.
   Cancer. 2025;131:e70071.
   

   >> Share

   
   May 2025
9. DUSKA LR, Lim J, Calderon Boyle TA, Guinter M, et al
   The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
   Cancer. 2025;131:e35821.
   

   >> Share

   
   
10. SCHNEIDER DT, Witowski A, Abele M, Benesch M, et al
    Testicular and ovarian Juvenile granulosa cell tumors in children and adolescents: Analysis of 113 patients registered to the German Registry for Rare Pediatric Tumors (STEP).
    Cancer. 2025;131:e35861.
    

    >> Share

    
    
11. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
    Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
    Cancer. 2025;131:e35862.
    

    >> Share

    
    April 2025
12. FREY MK, Liu JF
    Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancer.
    Cancer. 2025;131:e35800.
    

    >> Share

    
    March 2025
13. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    

    >> Share

    
    
14. NIERENGARTEN MB
    More evidence on benefits of HIPEC for recurrent ovarian cancer.
    Cancer. 2025;131:e35754.
    

    >> Share

    
    February 2025
15. HIPPALGAONKAR N, Huo D, Hoskins KF
    The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome.
    Cancer. 2025;131:e35722.
    

    >> Share

    
    
16. TEMKIN SM
    Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer.
    Cancer. 2025;131:e35735.
    

    >> Share

    
    January 2025
17. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    

    >> Share

    
    
18. LIU YL, Mathews CA, Simpkins F, Cadoo KA, et al
    Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
    Cancer. 2025;131:e35707.
    

    >> Share

    
    
19. MAHALINGAM D, Owonikoko TK, Delpassand E, Mulcahy MF, et al
    A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
    Cancer. 2025;131:e35680.
    

    >> Share

    
    
20. RICHARDS AR, Johnson CE, Montalvo NR, Alberg AJ, et al
    Comorbid conditions and survival among Black women with ovarian cancer.
    Cancer. 2025;131:e35694.
    

    >> Share

    
    November 2024
21. NIERENGARTEN MB
    Women with more severe forms of endometriosis have a nearly 10-fold higher risk of ovarian cancer.
    Cancer. 2024;130:3784.
    

    >> Share

    
    August 2024
22. SULLIVAN MW, Graves S, Adkoli A, Zhou Q, et al
    Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Cancer. 2024 Aug 16. doi: 10.1002/cncr.35523.
    

    >> Share

    
    June 2024
23. 
    Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials".
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35344.
    

    >> Share

    
    January 2024
24. MUTCH D, Voulgari A, Chen XM, Bradley WH, et al
    Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
    

    >> Share

    
    
25. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    

    >> Share

    
    December 2023
26. RIMEL BJ, Enserro D, Bender DP, Jackson CG, et al
    NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
    Cancer. 2023 Dec 21. doi: 10.1002/cncr.35151.
    

    >> Share

    
    
27. LUMISH MA, Kohn EC, Tew WP
    Top advances of the year: Ovarian cancer.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35135.
    

    >> Share

    
    November 2023
28. HINCHCLIFF EM, Knisely A, Adjei N, Fellman B, et al
    Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
    Cancer. 2023 Nov 27. doi: 10.1002/cncr.35126.
    

    >> Share

    
    October 2023
29. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    

    >> Share

    
    September 2023
30. NIERENGARTEN MB
    New standard of care for platinum-resistant ovarian cancer.
    Cancer. 2023;129:2601-2602.
    

    >> Share

    
    July 2023
31. WHITE VM, Alexiadis M, Eroh KD, Ackermann MK, et al
    How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor Survivor Sisters Facebook group member survey.
    Cancer. 2023;129:2224-2234.
    

    >> Share

    
    June 2023
32. GRISHAM RN, Manning-Geist BL, Chui MH
    The highs and lows of serous ovarian cancer.
    Cancer. 2023 Jun 27. doi: 10.1002/cncr.34903.
    

    >> Share

    
    
33. MEDINA HN, Penedo FJ, Joachim C, Deloumeaux J, et al
    Endometrial cancer risk and trends among distinct African descent populations.
    Cancer. 2023 Jun 26. doi: 10.1002/cncr.34789.
    

    >> Share

    
    
34. MIRZA MR, Gonzalez-Martin A, Graybill WS, O'Malley DM, et al
    Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Cancer. 2023;129:1846-1855.
    

    >> Share

    
    May 2023
35. KINDLER HL, Yoo HK, Hettle R, Cui KY, et al
    Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Cancer. 2023;129:1411-1418.
    

    >> Share

    
    March 2023
36. MANNING-GEIST BL, Kahn RM, Nemirovsky D, Girshman J, et al
    Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34753.
    

    >> Share

    
    
37. FOSTER KI, Shaw KRM, Jin J, Westin SN, et al
    Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
    Cancer. 2023 Mar 17. doi: 10.1002/cncr.34724.
    

    >> Share

    
    
38. GRISHAM RN, Manning-Geist BL, Chui MH
    Beyond the estrogen receptor: In search of predictive biomarkers for low-grade serous ovarian cancer.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34658.
    

    >> Share

    
    
39. HENDRIKSE CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, et al
    Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34661.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share